Gain Therapeutics, Inc. (GANX)
Last updated: 2026-10-21 16:26:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Gain Therapeutics, Inc. (GANX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $54.55M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.16 to $4.34. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$54.55M | |
$1.20 | |
$17.93 | |
$0.89 | |
$1.19 | |
307.23K | |
462.80K | |
-- | |
$4.34 | |
$1.16 | |
-- | |
-- |
Gain Therapeutics, Inc. (GANX) Stock Price Today
Gain Therapeutics, Inc. (GANX) is currently trading at $1.17 as of 2026-10-21 16:25:00, down 2.10% ($0.02) from the previous close of $1.19
During today's regular trading session, GANX has traded between $0.89 and $17.93, with a trading volume of 307.23K shares. The current price is near the lower end of today's range.
Gain Therapeutics, Inc. (GANX) 7-Day Stock Price Change
Over the past seven days, Gain Therapeutics, Inc. (GANX) moved from $1.57 to $1.17, representing a decline of 25.80% ($0.41).
The stock traded between $1.16 and $1.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 571.20 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
GANX 52-Week Price Position
Position in Range: 0.3%
GANX is currently trading at $1.17, placing it 0.3% of the way from its 52-week low of $1.16 to its 52-week high of $4.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Gain Therapeutics, Inc. (GANX)?
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Gain Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Gain Therapeutics, Inc. (GANX) Stock on MEXC
Eligible investors can buy real shares of Gain Therapeutics, Inc. (GANX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Gain Therapeutics, Inc. (GANX) stock price today?
2.Is GANX stock going up or down today?
3.What is GANX pre-market price?
4.What is GANX after-hours price?
5.Is GANX stock trading now?
6.Where does GANX sit relative to its 52-week high and low?
7.What sector is Gain Therapeutics, Inc. in?
8.What is Gain Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is GANX valued in terms of P/E ratio and EPS?
10.Does Gain Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
GANX Stock Calculator
Estimate the value between GANX shares and USD.
GANX Shares to USD
1.00 GANX shares = 1.165 USD
Calculations are estimates based on the latest available price and are for reference only.


